Thalidomide

Form: Capsules

Strength: 50 mg, 100 mg, 150 mg , 200 mg

Reference Brands: Thalomid®(US), Thalidomide Celgene(EU)

Category: Oncology Cancer Care

Thalidomide is an oral immunomodulatory drug (IMiD) approved in the US and EU for treating multiple myeloma and erythema nodosum leprosum (ENL). Marketed as Thalomid® in the US and Thalidomide Celgene in the EU, it is available in 50 mg, 100 mg, 150 mg, and 200 mg capsule strengths. With anti-angiogenic and anti-inflammatory properties, thalidomide is a key oncology asset in combination therapy. Due to its teratogenic risks, distribution is strictly regulated under REMS and controlled access programs. Ideal for B2B pharmaceutical companies seeking oncology portfolio expansion, licensing, or GMP-compliant API and finished formulation sourcing in global markets.